30. november 2022
The Danish and European medical cannabis industry is at a key inflection point. More European countries are adopting medical cannabis as an option for patients but also as an emerging industry that creates high-quality jobs from pharma to nursery production, drives exports, and attracts investment.
The future shape of these industries is still unknown, with no common European model to set the scope of development. National regulations and priorities continue to set the framework, with each country pursuing different priorities, regulations, and market structures.
After an experimental pilot program from 2018 to 2021, the Danish government established a permanent framework for medical cannabis production that started in 2022. A permanent framework reduces investment risk while also opening new opportunities for the development of new plant genetics, API production, and manufacturing final products.
The Danish medical cannabis industry is based on a medical cannabis model, with an open-ended licensing regime based on high quality standards but no limits to the scale of production. This model has made Denmark into a leading centre for medical cannabis production and aligns with the broader Life Sciences industry, which accounted for over 22 percent of Denmark’s exports in 2021.
In the broader Life Sciences industry, Denmark is a leading nation for R&D expenditure, clinical research, and drug development. This expertise provides a solid basis for the medical cannabis industry to draw on the strengths of the Danish Life Sciences industry. But it requires partnerships between industry and research to increase longer-term collaboration in research and development to commercial scientific results.
This is theme of the 3rd Annual Symposium on Medical Cannabis, hosted by the Danish Technological Institute and Invest in Denmark: Knowledge transfer - Science to Industry. The theme of this year’s Symposium on Medical Cannabis relates to the role of science and technology in building medical cannabis industry.
As has been the case every year, the Symposium is based on understanding the value chain “From Plant to Patient” and involves creating links between the various stakeholders that are involved in this dynamic industry.
When you participate in this event, your time will be used as co-financing for the project Innovationkraft, which is funded by the Danmarks Erhvervsfremmebestyrelse and the Uddannelses- og Forskningsstyrelsen at a standard rate. Read more about the project
Betaling / Participation feeFra
30. november 2022 kl. 09:20Til
30. november 2022 kl. 17:00